PTSD

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

A psychiatrist reflects on the recent flooding tragedy in Texas.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Researchers analyze single-cell communication in brains of people with PTSD, uncovering genetic variations that could lead to new treatments for this complex disorder.

Augmented reality can transform psychiatric treatment, enhancing exposure therapy for trauma and anxiety by simulating real-world environments and interactions.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Check out the pipeline updates from April!

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

How do psychiatrists and mental health professionals respond when faced with disaster? One psychiatrist shares his story.

Learn more about how to appropriately diagnose and categorize a spectrum of posttraumatic stress responses in children and adolescents.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Check out these 7 insights and perspectives on recognizing and treating PTSD.

A panelist discusses how a posttraumatic stress disorder (PTSD) diagnosis in clinical settings requires a comprehensive evaluation process that includes gathering detailed trauma history, assessing current symptoms through validated assessment tools, conducting differential diagnosis to rule out other conditions, and considering cultural and contextual factors that may influence symptom presentation.

A panelist discusses how clinicians employ a range of diagnostic tools for posttraumatic stress disorder (PTSD) assessment, including structured clinical interviews, standardized questionnaires such as the PCL-5, trauma screening instruments, and detailed behavioral observations to ensure accurate diagnosis and appropriate treatment planning.

A panelist discusses how diagnosing posttraumatic stress disorder (PTSD) presents unique challenges due to symptom overlap with other mental health conditions, varying presentation across different populations, and the often-delayed onset of symptoms following traumatic events.

A panelist discusses how posttraumatic stress disorder (PTSD) manifests through a complex web of symptoms, including intrusive memories, nightmares, hypervigilance, emotional numbness, and avoidance behaviors that significantly impact daily functioning and quality of life.

A panelist discusses how posttraumatic stress disorder (PTSD) alters key brain regions, such as the amygdala and hippocampus, with genetic predisposition, severity of trauma exposure, and lack of social support serving as critical risk factors that can influence both the likelihood of developing the condition and its neurobiological impact.

A panelist discusses how posttraumatic stress disorder (PTSD) permeates modern society at multiple levels, from individuals coping with personal trauma to collective trauma responses that shape community behaviors and social structures.

Learn more about best practices when treating comorbid trauma and psychosis.

Let’s compare treatment risks when managing mixed states.

Here are 4 means of coping with the diagnostic uncertainty of bipolar mixed states.

Traumatic life events are common among individuals who experience psychosis. Here's how best to assess and treat.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Patients who have experienced a perinatal loss are at increased risk of MDD, anxiety disorders, and trauma-related disorders.

There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.

Enter your email to check out this complicated case!

Is the complex posttraumatic stress disorder diagnosis being used to avoid the diagnosis of borderline personality disorder?

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.